I. Merino et al. / Il Farmaco 54 (1999) 255–264
263
by tetrahydroimidazo-[4,5,1-jk][1,4]benzodiazepin-2(1H)-one
and -thione derivatives, Proc. Natl. Acad. Sci. USA 88 (1991)
1451–1455.
were also made. On the third day of post-infection, the
medium was removed and the cells were fixed for 5 min
at r.t. with 200 ml of a PBS solution containing 1%
formaldehyde (Merck) and 0.2% glutaraldehyde
(Merck). After two washes with 0.9% NaCl (Merck),
the cells were incubated for 1 h at 37°C with 200 ml of
a reaction mixture containing X-gal (5-bromo-4-chloro-
[3] D.L. Romero, R.A. Morge, C. Biles, N. Berrios-Pena, P.D.
May, J.R. Palmer, P.D. Johnson, H.W. Smith, M. Busso, C.-K.
Tan, R.L. Voorman, F. Reusser, I.W. Althaus, K.M. Downey,
A.G. So, L. Resnick, W.G. Tarpley, P.A. Aristoff, Discovery,
synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A
novel class of non-nucleoside HIV-1 reverse transcriptase in-
hibitors, J. Med. Chem. 37 (1994) 999–1014.
3-indolyl-b-
D
-galactopyranoside,
Boehringer–Mann-
heim) (400 mg/ml), 4 mM potassium ferrocyanide
(Merck), and 2 nM MgCl2 (Merck) in PBS. After two
washes, 100 ml of 0.9% NaCl were added per well. The
plates were examined under the microscope and only
syncytia with three or more blue nuclei were counted in
the entire well.
[4] J. Balzarini, M.J. Pe´rez-Pe´rez, A. San Fe´lix, M.J. Camarasa, I.C.
Bathurst, P.J. Barr, E. De Clercq, Kinetics of inhibition of
human immunodeficiency virus type I (HIV-1) reverse transcrip-
tase by the novel HIV-1 specific nucleoside analogue [2%,5%-bis-O-
(t-butyldimethylsilyl)-b-D-ribofuranosyl]-3%-spiro-5%%-(4%%-amino-
1%%,2%%-oxathiole-2%%,2%%-dioxide)thymine (TSAO-T), J. Biol. Med.
267 (1992) 11831–11838.
[5] M. Cushman, A. Casimiro-Garc´ıa, E. Hejchman, J.A. Ruell, M.
Huang, C.A. Schaeffer, K. Williamson, W.G. Rice, R.W. Buck-
heit Jr., New alkenyldiarylmethanes with enhanced potencies as
anti-HIV agents which act as non-nucleoside reverse transcrip-
tase inhibitors, J. Med. Chem. 41 (1998) 2076–2089.
[6] E. De Clercq, HIV-1-specific RT inhibitors: highly selective
inhibitors of human immunodeficiency virus type 1 that are
specifically targeted at the viral reverse transcriptase, Med. Res.
Rev. 13 (1993) 229–258.
5.2.4. Cell toxicity
Viability of HLT4lacZ-1 cells was evaluated in the
presence of the synthesized products using a modified
cell lytic assay described previously [21]. It was per-
formed in parallel with the syncytia formation assay.
A total of 200 ml of medium containing different
concentrations of the products or medium (control
wells) were added to 10 000 HLT4lacZ-1 cells plated the
day before. On the third day, the wells were washed
three times with PBs, and cell lysis was detected by
staining the plate for 10 min at r.t., with 20 ml/well of a
methanol/water (1:4 v/v) solution containing 0.5% crys-
tal violet (Merck). Controls of wells have been prepared
by staining the plates without cells (blank wells). Three
washes were carried out by immersion of the plates in
PBS, changing the PBS of the container each time. The
plates were wiped and 100 ml/well of 0.1% SDS (sodium
dodecyl sulfate, Sigma) were added. After complete
desegregation of the cell membranes, the O.D. at 540
nm was read in a Titertek Multiskan II autoreader
(Flow) and the percentage of viability (% V) was
calculated.
[7] K. De Vreese, Z. Debyser, A.M. Vandamme, R. Pauwels, J.
Desmyter, E. De Clercq, J. Anne, Resistance of human im-
munodeficiency virus type
1 reverse transcriptase to TIBO
derivatives induced by site-directed mutagenesis, Virology 188
(1992) 900–904.
[8] V.V. Sardana, E.A. Emini, L. Gotlib, D.J. Graham, D.W.
Lineberger, W.J. Long, A.J. Schlabach, J.A. Wolfgang, J.H.
Condra, Functional analysis of HIV-1 reverse transcriptase
amino acids involved in resistance to multiple non-nucleoside
inhibitors, J. Biol. Chem. 267 (1992) 17526–17530.
[9] J.-P. Kleim, I. Winkler, M. Ro¨sner, R. Kisch, H. Ru¨bsamen-
Waigmann, A. Paerssens, G. Riess, In vitro selection for differ-
ent mutational patterns in de HIV-1 reverse transcriptase using
high and low selective pressure of the non-nucleoside reverse
transcriptase inhibitor HBY 097, Virology 231 (1997) 112–118.
[10] J. Balzarini, A. Karlsson, E. De Clercq, Human immunodefi-
ciency virus type 1 drug-resistance patterns with different 1-[(2-
hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives, Mol.
Pharmacol. 44 (1993) 694–701.
[11] J. Balzarini, A. Karlsson, M.J. Pe´rez-Pe´rez, M.J. Camarasa,
W.G. Tarpley, E. De Clercq, Treatment of human immunodefi-
ciency virus type 1 (HIV-1)-infected cells with combinations of
HIV-1-specific inhibitors results in a different resistance pattern
that does treatment with single-drug therapy, J. Virol. 67 (1993)
5353–5359.
Acknowledgements
This work was supported by the Upjohn Company
within the National Plan of Scientific and Technologi-
cal Investigation of Spain. The Gobierno Foral de
[12] E. De Clercq, HIV resistance to reverse transcriptase inhibitors,
Biochem. Pharmacol. 47 (1994) 155–169.
Navarra (Spain) granted
Merino.
a
scholarship to Isidro
[13] M. Font, A. Monge, A. Cuartero, A. Elorriaga, J.J. Mart´ınez de
Irujo, E. Alberdi, E. Santiago, I. Prieto, J.J. Lasarte, P. Sarobe,
F. Borra´s, Indoles and pyridazino[4,5-b]indoles as non-nu-
cleoside analog inhibitors of HIV-1 reverse transcriptase, Eur. J.
Med. Chem. 30 (1995) 963–971.
[14] A. Monge, M.J. Losa, M.J. Fidalgo, E. Nadal, A. Cuartero, C.
Sanmart´ın, E. Alvarez, I. Merino, M. Font, J.J. Mart´ınez de
Irujo, E. Alberdi, E. Santiago, I. Prieto, J.J. Lasarte, P. Sarobe,
F. Borra´s, New HIV-1 inhibitors, derived from 1,2-dihy-
droquinoline, Poster No. 213, 13th Int. Symp. Med. Chem.,
Paris, France, 1994.
References
[1] T. Miyasaka, H. Tanaka, M. Baba, H. Hayakawa, R.T. Walker,
J. Balzarini, E. De Clercq, A novel lead for specific anti-HIV-1
agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine, J.
Med. Chem. 32 (1989) 2507–2509.
[2] Z. Debyser, R. Pauwels, K. Andries, J. Desmyter, M. Kukla,
P.A.J. Janssen, E. De Clercq, An antiviral target on reverse
transcriptase of human immunodeficiency virus type 1 revealed
[15] A. Monge, I. Merino, M. Font, J.J. Mart´ınez de Irujo, E.
Alberdi, E. Santiago, I. Prieto, J.J. Lasarte, P. Sarobe, F. Borra´s,
Synthesis and anti-HIV-1 activities of new pyrimido[5,4-